A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Hodgkin Lymphoma Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT06504394
Trial Phases:	Phase II	Protocol IDs:	3475A-F65 (primary) NCI-2025-02909 2024-510969-42 2024-510969-42-00 MK-3475A-065 U1111-1302-8349
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06504394

Summary

The primary purpose of the study is to assess the pharmacokinetics (PK) profile of
pembrolizumab following subcutaneous (SC) injection of pembrolizumab coformulated with
hyaluronidase, and to evaluate the objective response rate (ORR) of pembrolizumab (+)
berahyaluronidase alfa SC in adult participants with Relapsed or Refractory Classical
Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell
Lymphoma (rrPMBCL). There is no formal hypothesis to be tested for this study.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.